Phenibut (β-Phenyl-γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse
This case report describes the development of withdrawal from phenibut, a gamma-aminobutyric acid-receptor type B agonist. Although phenibut is not an FDA-approved medication, it is available through online retailers as a nootropic supplement. There are reports of dependence in patients that misuse...
Saved in:
Main Authors: | Tania Ahuja, Ofole Mgbako, Caroline Katzman, Allison Grossman |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Case Reports in Psychiatry |
Online Access: | http://dx.doi.org/10.1155/2018/9864285 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Case of Phenibut Withdrawal Management and Detoxification Using Baclofen in the Outpatient Setting
by: Emma DiFiore, et al.
Published: (2024-01-01) -
The Design, Synthesis, and Characterization of Resveratrol Derivatives Modified by Different γ-Aminobutyric Acid Esters
by: Bing Ren Tian, et al.
Published: (2019-01-01) -
Electroacupuncture Improves Baroreflex and γ-Aminobutyric Acid Type B Receptor-Mediated Responses in the Nucleus Tractus Solitarii of Hypertensive Rats
by: Qi Zhang, et al.
Published: (2018-01-01) -
Reduced γ-Aminobutyric Acid and Glutamate+Glutamine Levels in Drug-Naïve Patients with First-Episode Schizophrenia but Not in Those at Ultrahigh Risk
by: Junjie Wang, et al.
Published: (2016-01-01) -
Effect of γ-ethyl-γ-phenyl-butyrolactone (EFBL), anticonvulsant and hypnotic drug, on mouse brain catecholamine levels
by: Rasgado Lourdes A. Vega, et al.
Published: (2017-06-01)